Has tamoxifen had its day?

Breast Cancer Research

Volumn 4, Issue 6, 2002, Pages 213-217

  Baum, Michael ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adjuvant therapy; Anastrozole; Aromatase inhibitors; Chemoprevention; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; TAMOXIFEN CITRATE;

BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CLINICAL STUDY; DEVELOPED COUNTRY; DRUG APPROVAL; DRUG MECHANISM; DRUG POTENTIATION; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; FEMALE; FRACTURE; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYSTEROSCOPY; MENOPAUSAL SYNDROME; MUSCULOSKELETAL DISEASE; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; THROMBOEMBOLISM; UNITED STATES; VAGINA BLEEDING; VAGINA DISCHARGE; VEIN THROMBOSIS;

BREAST NEOPLASMS; CLINICAL TRIALS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 0036440937     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr536     Document Type: Review

References (17)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988, 319:1681-1692.
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998, 90:1371-1387.
3. The ATAC Trialist Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
4. IBIS Working Party: First results from the IBIS-I breast cancer prevention trial. Lancet (in press).
5. Nolvadex Adjuvant Trial Organisation: Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Lancet 1983; i:257-261.
6. Cuzick J, Baum M: Tamoxifen and contralateral breast cancer [letter]. Lancet 1985, 2:282.
7. Sismondi P, Biglia N, Volpi E, Giai M, de Grandis T: Tamoxifen and endometrial cancer. Ann NY Acad Sci 1994, 734:310-321.
8. Bergman L, Beelan MLR, Gallee MPW, Hollema H, Benraadt J, van Leeuwen FE: Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000, 356:881-888.
9. Cutuli B, Petit JC, Fricker JP, Jung GM, Schumacher C, Velten M, et al.: Adjuvant tamoxifen in breast cancer treatment in postmenopausal women: occurrence of thromboembolic complications. Oncol Rep 1994, 1:59-63.
10. Howell A, Dowsett M: Recent advances in endocrine therapy of breast cancer. Br Med J 1997, 315:863-866.
11. Brown P: UK death rates from breast cancer fall by a third. BMJ 2000, 321:849.
12. Gottardis MM, Jordan VC: Development of tamoxifen stimulated growth of MCF-7 tumours in athymic mice after long-term anti-oestrogen administration. Cancer Res 1988, 48: 5183-5187.
13. Van Poznak C: How are bisphosphonates used today in breast cancer clinical practice? Semin Oncol 2001, 28(suppl 11):69-74.
14. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998, 351:1451-1467.
15. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998, 352:98-101.
16. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998, 352:93-97.
17. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001, 65:125-134.